Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
about
Incretin based therapeutics: connections to vascular biology and implications for potential cardiovascular disease prevention: Editorial to: "Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressinPeptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide.Brain-Defective Insulin Signaling Is Associated to Late Cognitive Impairment in Post-Septic Mice.The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.
P2860
Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
@en
Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
@nl
type
label
Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
@en
Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
@nl
prefLabel
Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
@en
Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
@nl
P2860
P1476
Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
@en
P2093
Gina J Ryan
Yolanda Hardy
P2860
P304
P356
10.1111/J.1365-2710.2010.01180.X
P577
2011-06-01T00:00:00Z